BUSINESS

LEO Pharma Earns Approval for Dovobet Foam Version

January 7, 2021

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

LEO Pharma said on January 6 that it has received Japanese regulatory approval for a new foam formulation of its psoriasis treatment Dovobet (calcipotriol hydrate + betamethasone dipropionate). Dovobet is already available in ointment and gel forms. The new version…

To read the full story

Dovobet Foam Formulation Filed in Japan: LEO Pharma/Kyowa Kirin
February 17, 2020

BUSINESS

RaQualia Expands Alliance with HK inno.N, Licenses Japan Rights to Reflux Therapy
December 15, 2025
Obesity Market Projected at 46.6 Billion Yen by 2040 as GLP-1s Fuel Growth: Fuji Keizai
December 15, 2025
Roche Diagnostics Taps Ex-Medtronic Japan VP Maeda as New CEO
December 15, 2025
Chugai to Launch US Partnering Office in January 2026
December 15, 2025
Scrap “Spillover,” “Special” Rules If G1 Rule Is Applied Early: Chugai CEO
December 15, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch

By Ken Yoshino

Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…